Recent insights into factors affecting remnant lipoprotein uptake
The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Remnant lipoproteins that persist in the bloodstream after each meal have become increasingly important contributors to atherosclerotic vascular disease, owing to the spread of overnutrition, underexertion, obesity, insulin resistance, and type 2 diabetes. Here, we review recent work that clarified long-standing controversies over the molecular mediators of remnant clearance by the liver, as well as their dysregulation - but possible correction - during alterations in caloric balance. RECENT FINDINGS: Two endocytic receptors, the syndecan-1 heparan sulfate proteoglycan (HSPG) and the LDL receptor, plus one docking receptor, SR-BI, significantly contribute to normal hepatic remnant catabolism. Compelling evidence exists for dysfunction of the syndecan-1 HSPG in diabetic states. The major molecular defect identified so far in poorly controlled type 1 diabetes is impaired hepatic HSPG assembly. In contrast, the primary defect in hepatic HSPGs in type 2 diabetes appears to arise from accelerated de-sulfation, owing to the induction of a sulfatase. Moreover, short-term caloric restriction restores hepatic expression of this sulfatase towards normal. SUMMARY: Correct identification of hepatic remnant receptors has finally allowed investigations of their molecular dysregulation in diabetes and related conditions. New work points to novel therapeutic targets to correct postprandial dyslipoproteinemia and its consequent arterial damage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“heparan sulfate proteoglycans in the liver space of Disse mediate clearance of triglyceride-rich lipoproteins independently of the well-known LDL receptor family members (954 -955).”
From Biological roles of glycans (2017) · cites this paper as [955]
In the citing paper
“Furthermore, an increased content of apoE in apoB containing lipoproteins may promote atherogenesis [62,63].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [62]
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor
Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., & Krieger, M. (1996) · Science · doi:10.1126/science.271.5248.518 · Cited by 2,026
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Self-citationBiology of the Syndecans: A Family of Transmembrane Heparan Sulfate Proteoglycans
Bernfield, M., Kokenyesi, R., Kato, M., Hinkes, M. T., Spring, J., Gallo, R. L., & Lose, E. J. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.002053 · Cited by 1,097
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,042
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Research works printed but not linked: 8
- Parhofer, 2000, J Clin Endocrinol Metab, 85, 4224
- Williams, 2001, Methods Mol Biol, 171, 457
- Stanford, 2009, J Clin Invest, 119, 3236
- Han, 2009, J Clin Invest, 119, 1029
- Murao, 2007, Am J Physiol, 294, E78
- Ybarra, 2001, Diabetes Metab, 27, 701
- Mooradian, 2009, Nat Clin Pract Endocrinol Metab, 5, 150
- Liu, 2004, Arterioscler Thromb Vasc Biol, 24, E
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“For example heparan sulfate proteoglycans in the liver space of Disse mediate clearance of triglyceride-rich lipoproteins independently of the well-known LDL receptor family members (954, 955).”
BackgroundLipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
“These results suggest that LNP siRNA systems containing ionizable cationic lipids are processed much like chylomicrons, which adsorb endogenous ApoE to trigger uptake into hepatocytes via several receptors that contain ApoE binding ligands.(24)”
BackgroundBorén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524
Self-citationNew insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
“The importance of the HSPG pathway has been questioned, but recent results demonstrate that dysfunction of syndecan-1 in animal models disrupts defective hepatic remnant clearance [222].”
BackgroundRecent advances in physiological lipoprotein metabolism
Ramasamy, I. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0358 · Cited by 235
“The syndecan-1 HSPG has been suggested as a major HSPG receptor for remnant lipoproteins in the liver [84].”
BackgroundLipids, lysosomes, and autophagy
Jaishy, B., & Abel, E. D. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067520 · Cited by 230
The regulation of ApoB metabolism by insulin
Haas, M. E., Attie, A. D., & Biddinger, S. B. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.04.001 · Cited by 187
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
“By contrast, apoC-III seems to inhibit the binding of remnants to hepatic receptors [26,27].”
BackgroundPostprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects
Cheng, Z., Huang, H., Yin, M., & Liu, H. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00602-1 · Cited by 184
Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis
Schwartz, E. A., & Reaven, P. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.021 · Cited by 130
Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125
“ApoE in apolipoprotein B (apoB) containing lipoproteins and in HDL particles can contribute to modulate the uptake in the liver via the interaction with surface proteoglycans in h epatic cells[62].”
Akhter, M. H., Khalilullah, H., Gupta, M., Alfaleh, M. A., Alhakamy, N. A., Riadi, Y., & Md, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101496 · Cited by 132
“Other studies have demonstrated that ionizable lipid nanoparticles bearing apolipoprotein-E (ApoE) ligand normally adsorb ApoE, resulting in a pronounced cell uptake into the liver cells mediated through several receptors withaffinity for the same [87].”
BackgroundTriglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease
Duran, E. K., & Pradhan, A. D. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa296 · Cited by 109
Bassendine, M. F., Sheridan, D. A., Bridge, S. H., Felmlee, D. J., & Neely, R. D. G. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0356-2 · Cited by 124
“Two endocytic receptors, the syndecan-1 HSPG [172] and the LDL receptor [173], plus one docking receptor, SR-BI, significantly contribute to normal hepatic TRL remnant catabolism [174].”
BackgroundThe Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 116
“HSPGs, most notably SCD1, are prominent endocytic receptors in liver involved in the clearance of TRL remnants [102,103].”
BackgroundFamilial dysbetalipoproteinemia: An underdiagnosed lipid disorder
Koopal, C., Marais, A. D., & Visseren, F. L. J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000316 · Cited by 101
Kinetics of plasma triglycerides in abdominal obesity
Björnson, E., Adiels, M., Taskinen, M., & Borén, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000375 · Cited by 106
Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics
Julve, J., Martín-Campos, J. M., Escolá‐Gil, J. C., & Blanco‐Vaca, F. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.004 · Cited by 118
“Other proteins associated with TRLs (i.e., apoB-48 [52], apoB100 [53], and apoA-V [34] as well as the lipolytic enzymes lipoprotein lipase and hepatic lipase [54]) also interact with HSPGs.”
BackgroundInfluentialApolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk
Morton, A. M., Koch, M., Mendivil, C. O., Furtado, J. D., Tjønneland, A., Overvad, K., Wang, L., Jensen, M. K., & Sacks, F. M. (2018) · JCI Insight · doi:10.1172/jci.insight.98045 · Cited by 91
Eliasson, B., Möller-Goede, D. L., Eeg‐Olofsson, K., Wilson, C., Cederholm, J., Fleck, P. R., Diamant, M., Taskinen, M., & Smith, U. (2012) · Diabetologia · doi:10.1007/s00125-011-2447-3 · Cited by 95
“As chylomicrons and VLDL particles and their remnants compete for the same catabolic pathways, both at the first step of lipolysis by LPL and at the second step of uptake by liver remnant receptors [21, 22], a reduced secretion of ApoB-48 particles by itself could improve the catabolic rate of VLDL1 particles by relea…”
BackgroundApolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans
Gonzales, J. C., Gordts, P. L. S. M., Foley, E. M., & Esko, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67398 · Cited by 79
“6, 7).”
Chen, K., & Williams, K. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444737 · Cited by 81
“1) (14, 19, 20), and as just noted, the C1 domain of syndecan-3 can bind Src family kinases (32).”
BackgroundInfluentialSelf-citationWilliams, K. J., & Wu, X. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.004 · Cited by 87
“Yet upon stimulation with insulin, the T2DM liver does not appropriately inhibit the secretion [298, 304, 420, 813, 814] nor accelerate the clearance [210, 290, 291, 293, 755, 756, 815, 816] of atherogenic apolipoprotein B-containing C-TRLs (Figure 3A).”
BackgroundSelf-citationFoley, E. M., Gordts, P. L. S. M., Stanford, K. I., Gonzales, J. C., Lawrence, R., Stoddard, N., & Esko, J. D. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301637 · Cited by 77
NOX4 Pathway as a Source of Selective Insulin Resistance and Responsiveness
Wu, X., & Williams, K. J. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.244525 · Cited by 67
Self-citationLaatsch, A., Panteli, M., Sornsakrin, M., Hoffzimmer, B., Grewal, T., & Heeren, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029385 · Cited by 65
“These TRL remnants are rapidly cleared by the liver in an insulin-dependent manner via binding of apoE and LPL to LRP1 or heparan sulfate proteoglycans (HSPG) [4–9].”
BackgroundHCV and the hepatic lipid pathway as a potential treatment target
Bassendine, M. F., Sheridan, D. A., Felmlee, D. J., Bridge, S. H., Toms, G. L., & Neely, R. D. G. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.004 · Cited by 77
“Once TG-rich lipoproteins (VLDL1 and CM) are hydrolysed by LPL, the resultant apoE-enriched TG-rich lipoprotein remnant particles are removed in the liver by the concerted action of a number of receptors [39,40].”
InfluentialChen, K., Liu, M.-L., Schaffer, L., Li, M., Boden, G., Wu, X., & Williams, K. J. (2010) · Hepatology · doi:10.1002/hep.23916 · Cited by 56
“Thus far, the SULF2 enzyme has been studied only within the context of growth factor and morphogen signaling,(21,22) with no prior suspicion of a role in lipoprotein biology or diabetes.(5,6) Preliminary reports of this work were presented at the International Symposium on Atherosclerosis (June 2009, Boston, MA)(23) a…”
BackgroundSelf-citationInhibition of hepatic sulfatase-2 In Vivo : A novel strategy to correct diabetic dyslipidemia
Hassing, C. H., Mooij, H., Guo, S., Monia, B. P., Chen, K., Kulik, W., Dallinga-Thie, G. M., Nieuwdorp, M., Stroes, E. S. G., & Williams, K. J. (2012) · Hepatology · doi:10.1002/hep.25580 · Cited by 49
“Moreover, our current results bolster the concept that diabetes dys-regulates a surprisingly small number of key molecules involved in the function of hepatic syndecan-1 as a receptor for TRL remnants.(15,25,33) After Sulf2 ASO administration, nonfasting plasma TG levels were decreased by 50%.”
BackgroundResultSelf-citationKoopal, C., Marais, A. D., Westerink, J., & Visseren, F. L. J. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.10.001 · Cited by 53
ApoCIII: A multifaceted protein in cardiometabolic disease
D'Erasmo, L., Di Costanzo, A., Gallo, A., Bruckert, E., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 50
Treatment of lipid disorders in obesity
Tonstad, S., & Després, J. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.83 · Cited by 53
microRNA‐379 couples glucocorticoid hormones to dysfunctional lipid homeostasis
de Guia, R. M., Rose, A. J., Sommerfeld, A., Seibert, O., Strzoda, D., Zota, A., Feuchter, Y., Krones, A., Sijmonsma, T., Kirilov, M., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201490464 · Cited by 48
“Indeed, chylomicron and VLDL remnants, which are similar in size and composition, have previously been found to be rapidly cleared by the liver (Mahley & Huang, 2007; Williams & Chen, 2010), which is consistent with our TRL/VLDL uptake studies.”
ResultThe role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia
Wu, X., Chen, K., & Williams, K. J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283544424 · Cited by 47
Self-citationRom, O., Grajeda‐Iglesias, C., Najjar, M., Abu‐Saleh, N., Volkova, N., Dar, D. E., Hayek, T., & Aviram, M. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.02.023 · Cited by 49
“Membranes were then blocked with 5% non-fat milk powder in TBS-T (0.125% Tween) for 1 h and exposed overnight to primary antibody at 4°C. Primary antibodies were diluted as follows: anti-LDLR (1:500), anti-CD36 (1:500), anti-SR-B1 (1:500), anti-SREBP1 (1:500), anti-DGAT1 (1:500), anti-actin (1:4000).”
BackgroundInfluentialShedding of Syndecan–1 From Human Hepatocytes Alters Very Low Density Lipoprotein Clearance
Deng, Y., Foley, E. M., Gonzales, J. C., Gordts, P. L. S. M., Li, Y., & Esko, J. D. (2011) · Hepatology · doi:10.1002/hep.24626 · Cited by 48
“1E,F), suggesting that either the extent of syndecan-1 silencing was incomplete or that other heparan sulfate proteoglycans can mediate binding and uptake.(6) Silencing of syndecan-4 did not result in reduction of binding, but other proteoglycans have not been examined (data not shown).”
BackgroundPlasma levels of apolipoprotein E and risk of ischemic heart disease in the general population
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.038 · Cited by 47
“Besides the contribution from the apoB/E membrane receptors, apoE in apoB containing lipoproteins and in HDL particles can contribute to modulate the uptake in the liver via the interaction with surface proteoglycans in hepatic cells [35].”
BackgroundMorton, A. M., Furtado, J. D., Mendivil, C. O., & Sacks, F. M. (2019) · JCI Insight · doi:10.1172/jci.insight.124620 · Cited by 49
Hepatic Heparan Sulfate Proteoglycans and Endocytic Clearance of Triglyceride-Rich Lipoproteins
Foley, E. M., & Esko, J. D. (2010) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(10)93010-x · Cited by 54
Hassing, H. C., Surendran, R. P., Derudas, B., Verrijken, A., Francque, S. M., Mooij, H. L., Bernelot Moens, S. J., Hart, L. M. '., Nijpels, G., Dekker, J. M., et al. (2014) · Obesity · doi:10.1002/oby.20682 · Cited by 40
“TRL metabolism involves a series of steps that culminate in the uptake of TRL-remnants by hepatocytes (8,11,12).”
BackgroundSelf-citationBrenta, G., Berg, G. A., Miksztowicz, V., Lopez, G. I., Lucero, D., Faingold, C., Murakami, M., Machima, T., Nakajima, K., & Schreier, L. E. (2016) · Thyroid · doi:10.1089/thy.2015.0140 · Cited by 42
“The RLP are components of highly modified TG-rich particles that result from the lipolysis of chylomicrons and very low density lipoprotein (VLDL) (17,18).”
Kegulian, N. C., Ramms, B., Horton, S. B., Trenchevska, O., Nedelkov, D., Graham, M. J., Lee, R. G., Esko, J. D., Yassine, H. N., & Gordts, P. L. S. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312723 · Cited by 38
Brito, V., Mellal, K., Portelance, S. G., Pérez, A., Soto, Y., deBlois, D., Ong, H., Marleau, S., & Vázquez, A. M. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300444 · Cited by 35
Hamer, I., Beersel, G. V., Arnould, T., & Jadot, M. (2012) · Current Drug Metabolism · doi:10.2174/138920012803762684 · Cited by 38
“(LRP1) or by HSPGs, located on the sinusoidal plasma membrane of hepatocytes [78].”
BackgroundMatikainen, N., Burza, M. A., Romeo, S., Hakkarainen, A., Adiels, M., Folkersen, L., Eriksson, P., Lundbom, N., Ehrenborg, E., Orho-Melander, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079473 · Cited by 31
“The importance of the HSPG pathway has been questioned, but recent results demonstrate that dysfunction of syndecan-1 HSPG in animal models disrupts defective hepatic remnant clearance [13].”
BackgroundAliyandi, A., Zuhorn, I. S., & Salvati, A. L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.599454 · Cited by 32
“…the past decades, nano-sized materials have emerged as powerful tools in many application fields, including nanomedicine, where they are used for therapeutic and diagnostic purposes (Peer et al., 2007; Cheng et al., 2015; D’Mello et al., 2017; Shi et al., 2017; Wolfram and Ferrari, 2019).”
BackgroundBissonnette, S., Salem, H., Wassef, H., Saint-Pierre, N., Tardif, A., Baass, A. W., Dufour, R., & Faraj, M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p023176 · Cited by 30
Role of Syndecans in Lipid Metabolism and Human Diseases
Леонова, Е. И., & Galzitskaya, O. V. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_10 · Cited by 27
Chen, K., Wu, Q., Hu, K.-W., Yang, C., Wu, X., Cheung, P., & Williams, K. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310358 · Cited by 27
Self-citationOniciu, D. C., Hashiguchi, T., Shibazaki, Y., & Bisgaier, C. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194568 · Cited by 28
“syndecan-1 are reduced, and Sulf-2 expression is elevated [41].”
BackgroundWalsh, M. T., Leo, E. D., Okur, İ., Tarugi, P., & Hussain, M. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.07.015 · Cited by 27
Doyon, M., Mathieu, P., & Moreau, P. R. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs325 · Cited by 25
Adal, M., Howe, R., Kassa, D., Aseffa, A., & Petros, B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195942 · Cited by 25
The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients
Nartea, R., Mitoiu, B. I., & Ghiorghiu, I. A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040205 · Cited by 24
“In conclusion, the role of LDL particles is to transport cholesterol synthesized by the liver (and initially transported by VLDL) to the extrahepatic tissues, ensuring their cholesterol needs [29,37,47,48].”
BackgroundApolipoprotein CIII and diabetes. Is there a link?
Christopoulou, E. C., Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3118 · Cited by 22
Triglyceride-Rich Lipoproteins
Kockx, M., & Kritharides, L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.008 · Cited by 22
Wang, X., Li, Z., Guo, Y., Wang, Y., Sun, G., Jiang, R., Kang, X., & Han, R. (2018) · Animal Biotechnology · doi:10.1080/10495398.2018.1479712 · Cited by 19
“the bloodstream are contributors to obesity, type 2 diabetes, overnutrition and atherosclerotic vascular disease.(12) The HS6ST3 gene is involved in lipid metabolism.”
BackgroundPlaner, D., Metzger, S., Zcharia, E., Wexler, I. D., Vlodavsky, I., & Chajek‐Shaul, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018370 · Cited by 20
Globular warming: how fat gets to the furnace
Williams, K. J., & Fisher, E. A. A. (2011) · Nature Medicine · doi:10.1038/nm0211-157 · Cited by 17
Self-citationAssociation of HS6ST3 gene polymorphisms with obesity and triglycerides: gene × gender interaction
Wang, K. S., Wang, L., Liu, X., & Min De, Z. E. N. G. (2013) · Journal of Genetics · doi:10.1007/s12041-013-0279-2 · Cited by 14
Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
Adiels, M., Mardinoğlu, A., Taskinen, M., & Borén, J. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00342 · Cited by 15
“The smaller chylomicron remnants are cleared from the circulation by the liver (Mahley and Ji, 1999; MacArthur et al., 2007; Williams, 2008; Williams and Chen, 2010).”
BackgroundGuardiola, M., Echeverría, P., González, M., Vallvé, J.-C., Puig, J., Clotet, B., Ribalta, J., & Negredo, E. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0061 · Cited by 10
“13 This increases the time that these lipoproteins remain in circulation and allows for the formation of more remnant-like particles (RLPs).”
Irawati, D., Mamo, J. C. L., Dhaliwal, S. S., Soares, M. J., Clark, K., & James, A. P. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0330-4 · Cited by 11
“Clearance of chylomicron remnants post hydrolysis is a highly efficient process that occurs principally via internalization by LDL receptor and LDL receptor-related protein 1 after remnants were bound to the HSPG of the surface of hepatocytes facilitated by apo E [41].”
BackgroundA New Beginning for Triglyceride-Lowering Therapies
Pradhan, A. D. (2019) · Circulation · doi:10.1161/circulationaha.119.038770 · Cited by 10
Role of sulfatase 2 in lipoprotein metabolism and angiogenesis
Dallinga, M. G., & Dallinga‐Thie, G. M. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000271 · Cited by 8
Irawati, D., Mamo, J. C. L., Soares, M. J., Clark, K., & James, A. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.018 · Cited by 6
Lipid Metabolism in Metabolic Syndrome
Borén, J., & Adiels, M. (2013) · Springer eBooks · doi:10.1007/978-3-319-01008-3_8 · Cited by 7
“Removal of lipoprotein from the circulation may occur by LDL-receptor mediated uptake or by heparin sulphate proteoglycans (Williams and Chen 2010).”
BackgroundHu, D., Mao, L., Tang, X., Jin, C., Guo, X., Luo, Q., Kuang, J., Zhang, T., Liu, R., Yuan, S., et al. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.12.013 · Cited by 5
Bubnova, M. G., Ezhov, M. N., Aronov, D. M., Galyavich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6364 · Cited by 6
Heparanase Inhibition Prevents Liver Steatosis in E0 Mice
Kinaneh, S., Hijaze, W., Mansour-Wattad, L., Hammoud, R. A., Zaidani, H., Kabala, A., & Hamoud, S. (2021) · Journal of Clinical Medicine · doi:10.2139/ssrn.3959681 · Cited by 5
Williams, K. J., & Fisher, E. A. A. (2015) · Wiley eBooks · doi:10.1002/9781118828533.ch24 · Cited by 6
Self-citationNi, P., Li, J., Duan, Y., Hu, P., Deng, Q., Hao, Y., Yang, Z., Han, L., Qi, Y., & Liu, J. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65441 · Cited by 3
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States
Pirillo, A., Norata, G. D., & Catapano, A. L. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_6 · Cited by 3
Michenaud, L., Marrié, N., Rimbert, A., Marmontel, O., Charrière, S., Gibert, C., Bouveyron, C., Mammi, J., Cariou, B., Moulin, P., et al. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0587 · Cited by 6
Pathogenesis of atherosclerosis: lipid metabolism
Wiklund, O., & Borén, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0011 · Cited by 3
Bubnova, M. G., Ezhov, M. V., Aronov, D. M., Galyаvich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Cardiosomatics · doi:10.17816/cs688224 · Cited by 1
Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update
Ttrai, P., & Kovalszky, I. (2012) · InTech eBooks · doi:10.5772/28030 · Cited by 1
“Endocytic clearance of triglyceride-rich lipoprotein remnants, a major metabolic task of hepatocytes, is mediated by HS as a receptor, and syndecan-1 has been identified as the primary HSPG involved in this process (Stanford et al., 2009; Williams & Chen, 2010).”
Fatty acid metabolism in the metabolic syndrome : effects of dietary fat quantity and quality
van Hees, A. M. J. (2011) · Research Publications (Maastricht University) · doi:10.26481/dis.20111111ah
Bamji‐Mirza, M. (2011) · Library and Archives Canada (Government of Canada) · doi:10.20381/ruor-4710
Genetic and functional studies of MTTP and PLIN2 in relation to metabolic and cardiac dysfunction
Aminoff, A. (2012) · Figshare
Lipoproteínas de baja densidad y remanentes: diferentes mecanismos de oxidación y aterogénesis
Wikinski, R., Schreier, L. E., Berg, G. A., Brites, F. D., Lopez, G. I., González, A. I., Zago, V., & Muzzio, M. L. (2010) · Redalyc (Universidad Autónoma del Estado de México)
Genetic and metabolic studies of APOE, PCSK9, TM6SF2 and PNPLA3
Mahdessian, H. (2014) · Figshare
Delgado-Roche, L., Hernández-Matos, Y., García-Simón, G., Vázquez-López, A. M., & Pardo-Andreu, G. L. (2015) · Revista de Ciencias Farmacéuticas y Alimentarias
Bermúdez, E., & Patricia, J. (2015) · TDX (Tesis Doctorals en Xarxa)
Recent insights into factors affecting remnant lipoprotein uptake: Erratum
(2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833da2de
HIGH-DENSITY LIPOPROTEINS AND APOLIPOPROTEIN A-I WITH AORTIC ENDOTHELIAL CELLS
Ohnsorg, P. M. (2011)
Dysrégulations de la production et de la clairance des lipoprotéines riches en triglycérides
Marmontel, O. (2018) · theses.fr (ABES) · doi:10.70675/bbd72f7dz89b7z4e60z8948z624ca506d486
“Tous les ligands des récepteurs possèdent un domaine hydrophobe pour adhérer aux lipoprotéines et un domaine cationique chargé négativement qui interagit avec les récepteurs hépatiques spécifiques (263).”
BackgroundInfluentialАнатольевич, С. А., Meshkov, A. N., & Владиславович, Е. М. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6179
Dysbetalipoproteinaemia in genetically predisposed Ghanaians
Ateko, R. O., Marais, A. D., Blom, D. J., Adadey, S. M., Thomford, N. E., & Blackhurst, D. M. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02787-0
“…lipoprotein remnants, derived from chylomicron and very low-density lipoprotein (VLDL) remnants, via apoE-dependent binding to hepatic receptors such as the low-density lipoprotein receptor (LDLR), LDL receptor-related protein (LRP) and heparan sulfate proteoglycans (HSPG) [10, 11].”
Filippo, M. D. (2014) · theses.fr (ABES) · doi:10.70675/72090dcbz5e73z41d4zaaa1z93311c54faa8 · Cited by 1
Characterization of Hepatitis C Virus interaction with heparan sulfate proteoglycans
Xu, Y. (2014) · theses.fr (ABES) · doi:10.70675/b8c9dc27z15cfz4921zad5czee757d47d341
Бубнова, М. Г., Владиславович, Е. М., Dm, A., Сарварович, Г. А., Савельевич, Г. В., Дупляков, Д. В., Зафираки, В. К., Станиславовна, К. Н., Васильевич, К. В., Александрович, К. Г., et al. (2025) · Cardiosomatics
Metadata
- Authors
- Williams, K. J., & Chen, K.
- Affiliations
- Temple University (US)
- Corresponding author
- Williams, Kevin Jon
- Venue
- Current Opinion in Lipidology
- Published
- 2010-06
- Volume
- 21
- Issue
- 3
- Pages
- 218-228
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W1966190991
- Cited by
- 91
- References
- 135
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 2 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 5 · 2016: 12 · 2015: 10 · 2014: 4 · 2013: 11 · 2012: 12
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL 38956, R01HL094277, R01HL073898, HL73898, HL94277)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK043396)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- remnant lipoproteins, syndecan-1, heparan sulfate proteoglycans, LDL receptor, scavenger receptor class B type I, type 2 diabetes, type 1 diabetes, sulfatase, caloric restriction, atherosclerosis, energy balance
- MeSH terms
- Amino Acid Sequence, Animals, Biological Transport, Diabetes Mellitus, Humans, Lipoproteins, Liver, Molecular Sequence Data, Receptors, LDL, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.